Dynamic Technology Lab Private Ltd Acquires Shares of 3,120 Glaukos Corporation $GKOS

Key Points

• Dynamic Technology Lab Private Ltd has acquired 3,120 shares of Glaukos Corporation, valued at approximately $307,000, marking its entry into the stock during the 1st quarter.
• Several large investors, including Deutsche Bank AG and Lazard Asset Management LLC, have significantly increased their holdings in Glaukos during the previous quarter, enhancing institutional ownership to 99.04%.
• Glaukos reported earnings of ($0.24) per share for the last quarter, slightly beating analyst expectations, with a revenue increase of 29.7% year-over-year, while maintaining a negative net margin of 21.43%.

Dynamic Technology Lab Private Ltd bought a new stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 3,120 shares of the medical instruments supplier's stock, valued at approximately $307,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Deutsche Bank AG boosted its stake in shares of Glaukos by 49.6% during the 4th quarter. Deutsche Bank AG now owns 43,859 shares of the medical instruments supplier's stock worth $6,576,000 after acquiring an additional 14,540 shares in the last quarter. Focus Partners Wealth acquired a new position in Glaukos in the 4th quarter worth about $379,000. Lazard Asset Management LLC boosted its position in Glaukos by 228.2% during the fourth quarter. Lazard Asset Management LLC now owns 13,911 shares of the medical instruments supplier's stock worth $2,085,000 after purchasing an additional 9,673 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Glaukos by 3.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,349 shares of the medical instruments supplier's stock valued at $4,551,000 after purchasing an additional 984 shares during the period. Finally, Nuveen Asset Management LLC grew its holdings in Glaukos by 0.9% in the fourth quarter. Nuveen Asset Management LLC now owns 314,963 shares of the medical instruments supplier's stock valued at $47,226,000 after purchasing an additional 2,665 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Trading Up 4.5%

Shares of NYSE GKOS traded up $3.73 during mid-day trading on Thursday, reaching $85.83. 947,492 shares of the company's stock were exchanged, compared to its average volume of 692,935. The company's 50-day moving average is $91.79 and its 200-day moving average is $94.88. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The firm has a market capitalization of $4.92 billion, a price-to-earnings ratio of -52.02 and a beta of 0.77. Glaukos Corporation has a 52-week low of $77.10 and a 52-week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The business had revenue of $124.12 million during the quarter, compared to analyst estimates of $115.49 million. During the same period last year, the business posted ($0.52) earnings per share. The company's quarterly revenue was up 29.7% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. Analysts expect that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Zacks Research lowered shares of Glaukos from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 15th. BTIG Research reaffirmed a "buy" rating and issued a $118.00 price target on shares of Glaukos in a research note on Wednesday, September 10th. Mizuho set a $130.00 price objective on Glaukos in a report on Thursday, July 31st. William Blair upgraded Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. Finally, Wells Fargo & Company increased their target price on Glaukos from $86.00 to $92.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $124.83.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.